Loading stock dataβ¦
EVO
$1.81-0.04 (-2.42%)
Market OpenUpdated 9:45 AM EDT
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Evotec SE in the Healthcare sector is trading at $1.82 with a market capitalization of $963M. Wall Street consensus targets $4.32 (3 analysts), implying a +137.3% move over the next 12 months. The stock is currently near its 52-week low of $1.80, remaining 35.7% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +137.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $156.64Mβ | $253.27Mβ | $163.89Mβ | $171.24Mβ | $199.98M |
| Gross Profit | -$1.57Mβ | $78.46Mβ | -$62,000β | $8.59Mβ | $33.24M |
| Operating Income | -$46.42Mβ | $37.21Mβ | -$44.61Mβ | -$28.60Mβ | -$19.82M |
| Net Income | -$121.94Mβ | $14.62Mβ | -$43.09Mβ | -$43.48Mβ | -$31.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Β Evotec Biologics. The company is developing...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$962.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.71%
Volume
Today's trading volume
4,512
Recent News
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention
Why Odyssey Therapeutics Stock Is Back In Focus Odyssey Therapeutics (ODTX) is drawing attention after reporting second quarter 2026 results that showed a larger net loss alongside a sharp change in reported loss per share from continuing operations. For the quarter ended June 30, 2026, Odyssey Therapeutics reported a net loss of US$52.79 million compared with US$41.24 million a year earlier. Basic and diluted loss per share from continuing operations was US$1.74, while the prior year figure...
Evotec and Odyssey collaborate on AI-enabled R&D
The partnership intends to leverage complementary scientific strengths to boost early-stage research and produce new medicines.
Health Care Roundup: Market Talk
Find insight on Hikma Pharmaceuticals, Evotec and more in the latest Market Talks covering health care.
Evotec SE (EVO) Q2 2026 Earnings Call Highlights: Navigating Revenue Declines and Strategic ...
Despite a challenging quarter with revenue declines, Evotec SE (EVO) focuses on liquidity growth, strategic partnerships, and cost-saving initiatives to drive future success.
Evotec Q2 Earnings Call Highlights
Evotec (NASDAQ:EVO) reported preliminary unaudited results for the second quarter and first half of 2026 and lowered its full-year outlook, citing delayed strategic partnership revenue, slower conversion of commercial activity into revenue and longer timelines for new partnership agreements. Chief